RWE Wins Two Offshore Wind Leases In Germany

German utility RWE AG (RWEOY.PK) Friday said it was awarded two offshore wind leases with a total of 525 megawatts or MW in the by German offshore auction.

The German Federal Network Agency informed that RWE secured a lease (N-3.7) for an offshore wind farm with a potential capacity of 225 MW in the North Sea, as well as a second site in the Baltic Sea (O-1.3) with a potential capacity of 300 MW.

Regarding the Baltic Sea (O-1.3) lease, the company noted that a competitor holds so-called step-in-rights for the lease, and a final award decision may not be made until the beginning of November.

RWE and its partner Northland Power hold step-in-rights for another of auctioned sites, N-3.8 in the North Sea, which has a capacity of 433 MW.

The company intends to leverage synergies from its existing offshore wind farms in the delivery of both projects, which are scheduled to go into operation in 2026.

RWE operates five offshore wind farms off the German coast, while a further project - Kaskasi - is under construction.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT